In the last trading session, 8,933,393 Atossa Therapeutics, Inc. (NASDAQ:ATOS) shares changed hands as the company’s beta touched 2.28. With the company’s per share price at $2.05 changed hands at -$0.11 or -0.05% during last session, the market valuation stood at $247.69 Million. ATOS’s last price was a discount, traded about -147.81% off its 52-week high of $5.08. The share price had its 52-week low at $0.81, which suggests the last value was 60.49% up since then. When we look at Atossa Therapeutics, Inc.’s average trading volume, we note the 10-day average is 11.32 Million shares, with the 3-month average coming to 25.01 Million.
Analysts gave the Atossa Therapeutics, Inc. (ATOS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 2 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended ATOS as a Hold, 2 felt it is a Buy and none rated the stock as Underweight. Atossa Therapeutics, Inc.’s EPS for the current quarter is expected to be -$0.27.
Atossa Therapeutics, Inc. (NASDAQ:ATOS) trade information
Although ATOS has turned red as seen at the end of in last trading. With action -5.09%, the performance over the past five days has been red. The jump to weekly highs of $2.49- on Tuesday, Mar 23 added 17.67% to the stock’s daily price. The company’s shares are showing year-to-date upside of 1.16%, with the 5-day performance at -0.18% in the red. However, in the 30-day time frame, Atossa Therapeutics, Inc. (NASDAQ:ATOS) is -0.25% down. Looking at the short shares, we see there were 6.59 Million shares sold at short interest cover period of 0.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is $6.25, meaning bulls need an upside of 204.88% from its current market value. According to analyst projections, ATOS’s forecast low is $5 with $7.5 as the target high. To hit the forecast high, the stock’s price needs a +265.85% upsurge from its current level, while the stock would need to tank 143.9% for it to hit the projected low.
Atossa Therapeutics, Inc. (ATOS) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 53.3%. The 2021 estimates are for Atossa Therapeutics, Inc. earnings to increase by 63.1%, but the outlook for the next 5-year period is at 0% per year.
Atossa Therapeutics, Inc. (NASDAQ:ATOS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.12% of Atossa Therapeutics, Inc. shares while 6.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.49%. There are 24 institutions holding the Atossa Therapeutics, Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Dec 30, 2020, the company held 0.5% of the shares, roughly 518.11 Thousand ATOS shares worth $492.2 Thousand.
Renaissance Technologies, LLC holds the second largest percentage of outstanding shares, with 0.48% or 492.8 Thousand shares worth $468.16 Thousand as of Dec 30, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 397420 shares estimated at $377.55 Thousand under it, the former controlled 0.38% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.12% of the shares, roughly 120.69 Thousand shares worth around $114.65 Thousand.